← Back to Clinical Trials
RecruitingNCT04593082

Obesity and Pediatric Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionMultiple Sclerosis
SponsorUniversity of Virginia
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment116
SexALL
Min Age10 Years
Max Age20 Years
Start Date2021-06-03
Completion2025-06-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease expression and course is unknown. This study will evaluate the relationship between obesity, obesity-derived inflammatory mediators, and imaging metrics of MS severity in children. Understanding how childhood obesity contributes to MS severity/progression may yield fundamental insights into disease pathobiology - which may thereby lead to effective strategies for halting its progression in its earliest stages.

Eligibility Criteria

Pediatric MS subjects will meet below inclusion and exclusion criteria: Inclusion Criteria: * Ability to provide informed consent (or assent for minors) * Relapsing-remitting MS diagnosis per 2017 McDonald criteria * Ages ≥ 10 years to ≤ 20 years * Diagnosis of MS or first clinical symptom of MS (whichever comes first) within ≤ 36 months from the time of enrollment. Exclusion Criteria: * Progressive form of MS * Patients with an active, chronic disease of the immune system other than MS * Conditions affecting the central nervous system (CNS) white matter (e.g. leukodystrophy) or for whom another condition may better explain imaging abnormalities (e.g. lupus) * Myelin oligodendrocyte glycoprotein (MOG) antibodies on serologic testing * Corticosteroid exposure within 30 days of study enrollment Control subjects (Aim 2) will meet the below inclusion and exclusion criteria: Inclusion Criteria: * Ability to provide informed consent (or assent for minors) * Age-, sex-, \& BMI-matched to pedi

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology